Trial Comparing Niraparib-bevacizumab-TSR042 and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Condition:   Ovarian Cancer Interventions:   Drug: Niraparib;   Drug: Bevacizumab;   Drug: TSR042;   Drug: Carboplatin;   Drug: Paclitaxel Sponsor:   Nordic Society for Gynaecologic Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials